In addition to being critical for the maintenance of various cancers, EZH2 has also been shown to exert a tumour‐suppressive function: loss‐of‐function mutations in many PRC2 members are prevalent in various cancers, and mouse models deficient for EZH2 or other PRC2 components show cancer predisposition 18, 82. This evidence concerns the gene EZH2 and neoplasm.